Associated tags: GIA, Breast, Register, Medical imaging, MM, FDA, NIH, Research, QT, Woman, Breast cancer, Radiation
Oncology,
Medical Devices,
Health,
Surgery,
Research,
Science,
Breast cancer,
Cancer,
Partnership,
Patient,
Woman,
Medical imaging QT Imaging Holdings, Inc. (NASDAQ:QTI) (“QT Imaging”) a medical device company engaged in research, development, and commercialization of innovative body imaging systems, together with its strategic business and distribution partner, is proud to announce its partnership with The Vincere Cancer Center in Scottsdale, AZ.
Key Points:
- QT Imaging Holdings, Inc. (NASDAQ:QTI) (“QT Imaging”) a medical device company engaged in research, development, and commercialization of innovative body imaging systems, together with its strategic business and distribution partner, is proud to announce its partnership with The Vincere Cancer Center in Scottsdale, AZ.
- The Vincere Cancer Center is a top cancer center in the U.S.
- Dr. Shukla, a long-standing supporter of QT Imaging and its technology, applies the QT Imaging Breast Acoustic CT™ Scanner in their breast screening environment.
- The partnership with Vincere Cancer Center represents the continuation of our swift commercialization plan since the company went public two months ago.”
QT Imaging Holdings, Inc. (NASDAQ:QTI), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is proud to announce the Opening Bell Ceremony at the Nasdaq MarketSite in Times Square.
Key Points:
- QT Imaging Holdings, Inc. (NASDAQ:QTI), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is proud to announce the Opening Bell Ceremony at the Nasdaq MarketSite in Times Square.
- In honor of the occasion, Dr. Raluca Dinu, Chief Executive Officer, will ring the Opening Bell.
Research,
Medical Devices,
Women,
Clinical Trials,
Biotechnology,
Radiology,
Consumer,
Health,
Science,
Oncology,
FDA,
University,
ROC,
Cancer,
Woman,
Breast cancer,
Breast disease,
Tomosynthesis,
MD,
3D,
DBT,
QTI,
Patient,
MRMC,
AUC,
Recall,
Medical imaging The study found that QTI’s Breast Acoustic CTTM is similarly effective as digital breast tomosynthesis (DBT), also known as 3D mammography, in that the area under receiver operating characteristic curve (AUC) was statistically non-inferior for QTI scan compared with DBT for the AUC difference margin of -0.05.
Key Points:
- The study found that QTI’s Breast Acoustic CTTM is similarly effective as digital breast tomosynthesis (DBT), also known as 3D mammography, in that the area under receiver operating characteristic curve (AUC) was statistically non-inferior for QTI scan compared with DBT for the AUC difference margin of -0.05.
- This means that QTI technology is non-inferior to DBT in the detection of breast lesions as a whole, with high specificity in determining benign cysts and thus decreasing benign recall rates.
- Unfortunately, routine screening mammograms are not recommended for women under 40 because risks outweigh potential benefits at this young age.
- Fortunately, the now published results suggest that QTI’s technology can be a much-needed potential alternative to mammography for women too young to undergo mammography screening.
Oncology,
Medical Devices,
Health,
Consumer,
Women,
Biotechnology,
FDA,
Radiation,
Woman,
Internal medicine,
Breast,
Partnership,
Research,
3D,
Patient,
Medicine,
Medical director,
Breast cancer,
Medical imaging The Center for New Medicine is one of the largest integrative medical clinics in North America, providing a personalized approach to health care including cancer prevention, its early detection, and internal medicine.
Key Points:
- The Center for New Medicine is one of the largest integrative medical clinics in North America, providing a personalized approach to health care including cancer prevention, its early detection, and internal medicine.
- With the incorporation of the QT Imaging Breast Acoustic CT™ Scanner, the Center for New Medicine will expand their innovative services in women’s and breast health.
- There is tremendous opportunity for new technology to advance women’s health, especially in breast cancer detection and treatment.
- QT Imaging Breast Acoustic CT™ Scanner is the only 3D imaging device to receive FDA clearance for use as a transmission and reflection low frequency soundwaves imaging system for a patient’s breast.
Dr. Dinu will serve in this position for one year, when the Company will reevaluate this strategic position.
Key Points:
- Dr. Dinu will serve in this position for one year, when the Company will reevaluate this strategic position.
- Dr. John Klock will step down as Chief Executive Officer, but will remain part of the Board of Directors, transitioning to serve as a Company advisor.
- As previously announced, Anastas (Stas) Budagov will take the position of Chief Financial Officer.
- Mr. Budagov served as a contracting Chief Financial Officer with QT Imaging, Inc. since December 2023 and accepted a permanent full-time job with the public company.
QT Imaging Holdings, Inc. (NASDAQ: QTI), a medical device company engaged in the research, development, and commercialization of innovative body imaging systems, updated the ticker symbol for its warrants to “QTIWW”, currently trading in the over-the-counter (OTC) market, effective as of March 11, 2024.
Key Points:
- QT Imaging Holdings, Inc. (NASDAQ: QTI), a medical device company engaged in the research, development, and commercialization of innovative body imaging systems, updated the ticker symbol for its warrants to “QTIWW”, currently trading in the over-the-counter (OTC) market, effective as of March 11, 2024.
- The company’s units formerly trading in the OTC market under “GIAFU” have been delisted as of March 11, 2024, as each unit was split into one share of common stock and one warrant upon the closing of its business combination on March 4, 2024.
Research,
Medical Devices,
Women,
Engineering,
Manufacturing,
Radiology,
Consumer,
Health,
Science,
Oncology,
ACT,
NAC,
Partnership,
Patient,
Champaign–Urbana metropolitan area,
Sunnybrook Health Sciences Centre,
Biomarker,
University of Illinois Urbana-Champaign,
Cancer,
University,
Doctor of Philosophy,
Electricity,
MD,
Computer engineering,
Risk,
Woman,
Breast cancer,
Safety,
Radiation,
Bangladesh Technical Education Board,
Radiation therapy,
Grainger College of Engineering,
Medical imaging This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach capable of accurate and early identification of response of breast cancer patients to neoadjuvant chemotherapy (NAC).
Key Points:
- This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach capable of accurate and early identification of response of breast cancer patients to neoadjuvant chemotherapy (NAC).
- As part of this grant, Breast Acoustic CT™ (ACT) quantitative images with independent biomarkers known to be sensitive to cancer will be collected, and the response of cancer to therapy, will be derived from quantitative ultrasound based on backscatter analysis.
- This collaboration also addresses the ongoing clinical need in breast cancer therapy for the development of an inexpensive, robust, and accurate technique to identify the response, within weeks, of breast cancer to neoadjuvant chemotherapy.
- The early identification of non-responders to NAC or any cancer treatment remains a highly significant medical problem and necessary for adaptive precision medicine.
Oncology,
Medical Devices,
Health,
Hospitals,
General Health,
Radiology,
Bangladesh Technical Education Board,
Injection,
NIH,
3D,
Sale,
Functional medicine,
Safety,
Mammography,
QTI,
Radiation exposure,
Patient,
Research,
Partnership,
Medical imaging The QTI Breast Acoustic CT™ System, featuring the trademarked Breast ACT™ technology, is an advancement in breast imaging.
Key Points:
- The QTI Breast Acoustic CT™ System, featuring the trademarked Breast ACT™ technology, is an advancement in breast imaging.
- Lastly, this NIH-funded technology represents a significant advancement in healthcare imaging, setting a new standard in breast imaging excellence.
- “The QTI Breast Acoustic CT™ System represents a leap forward in patient-centric breast imaging.
- This strategic partnership marks a significant achievement for QTI and serves as a testament to the advancements in breast imaging technology.
Health,
General Health,
Acquisition,
Bangladesh Technical Education Board,
Hospital,
Injection,
Breast cancer,
DLA Piper,
Artificial intelligence,
BPM,
FDA,
Growth,
Radiation,
Private,
Annual general meeting,
QT,
Safety,
Attention,
Partner,
Physics,
PPE,
Mammography,
Business analyst,
QTI,
GIA,
Patient,
Radiation exposure,
United,
LLP,
Software,
Research,
MRI,
Partnership,
Medical imaging QT Imaging Holdings, Inc. a medical device company engaged in the research, development, and commercialization of innovative body imaging systems using low frequency sound waves, and GigCapital5, Inc. (“GigCapital5”; Nasdaq: GIA, GIAFW), a Private-to-Public Equity (PPE)™ entity also known as special purpose acquisition company (“SPAC”), today announced the completion of their previously announced business combination (the “Business Combination”).
Key Points:
- QT Imaging Holdings, Inc. a medical device company engaged in the research, development, and commercialization of innovative body imaging systems using low frequency sound waves, and GigCapital5, Inc. (“GigCapital5”; Nasdaq: GIA, GIAFW), a Private-to-Public Equity (PPE)™ entity also known as special purpose acquisition company (“SPAC”), today announced the completion of their previously announced business combination (the “Business Combination”).
- The Business Combination was approved at the Annual Meeting of GigCapital5’s stockholders on February 20, 2024.
- Upon completion of the Business Combination, the combined company changed its name to QT Imaging Holdings, Inc. (“QT Imaging”).
- The QT Imaging Breast Acoustic CT™ Scanner, with its already granted FDA clearance as adjunct to mammography, sets a new standard in breast imaging excellence.
Retrieved on:
Thursday, February 29, 2024
Professional Services,
Medical Supplies,
Health,
Medical Devices,
Finance,
General Health,
Banking,
Acquisition,
DLA Piper,
BPM,
FDA,
Growth,
Private,
QT,
Partner,
PPE,
Business analyst,
GIA,
LLP,
Diagnosis,
Research,
Partnership,
Management GigCapital5, Inc. (“GigCapital5”; Nasdaq: GIA), a Private-to-Public Equity (PPE)™ entity also known as special purpose acquisition company (“SPAC”), today announced that the completion of their previously announced business combination (the “Business Combination”) with QT Imaging, Inc. (“QT Imaging”), a technology company engaged in an innovative automated breast imaging system producing high-resolution transmission ultrasound images, will take place on March 4, 2024.
Key Points:
- GigCapital5, Inc. (“GigCapital5”; Nasdaq: GIA), a Private-to-Public Equity (PPE)™ entity also known as special purpose acquisition company (“SPAC”), today announced that the completion of their previously announced business combination (the “Business Combination”) with QT Imaging, Inc. (“QT Imaging”), a technology company engaged in an innovative automated breast imaging system producing high-resolution transmission ultrasound images, will take place on March 4, 2024.
- Upon completion of the Business Combination, the combined company will change its name to QT Imaging Holdings, Inc. (“QT Imaging Holdings”).
- QT Imaging is a medical device company engaged in the research, development and commercialization of innovative body imaging systems using low energy sound.
- Brown Rudnick LLP is serving as legal counsel and BPM LLP is serving as auditor to QT Imaging.
